Phaseline

Companies › Shenzhen Beike Bio-Technology

Shenzhen Beike Bio-Technology: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 4 Phase 1; Immunology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
hUC-MSCs treatment (low dose)
Allogeneic umbilical cord-derived mesenchymal stem cells
–Phase 1Systemic Lupus Erythematosus (SLE)Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07041801hUC-MSCs treatment (low dose)Phase 1Systemic Lupus Erythematosus (SLE)ImmunologySep 2027
NCT07041801hUC-MSCs treatment (low dose)Phase 1Systemic Lupus Erythematosus (SLE)ImmunologySep 2027
NCT07041801hUC-MSCs treatment (low dose)Phase 1Systemic Lupus Erythematosus (SLE)ImmunologySep 2027
NCT07041801hUC-MSCs treatment (low dose)Phase 1Systemic Lupus Erythematosus (SLE)ImmunologySep 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.